1997
Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study
MCDOUGLE C, HOLMES J, BRONSON M, ANDERSON G, VOLKMAR F, PRICE L, COHEN D. Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 1997, 36: 685-693. PMID: 9136504, DOI: 10.1097/00004583-199705000-00020.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderDevelopmental disordersRisperidone treatmentClinical Global Impression ScaleOpen-label studyOpen-label trialPlacebo-controlled studyCommon side effectsEfficacy of risperidoneShort-term safetyGlobal Impression ScaleGlobal improvement itemBehavioral ratingsChildhood disintegrative disorderSocial relatednessTreatment of childrenAsperger's disorderRepetitive behaviorsAutistic disorderBehavioral symptomsBaseline visitMean ageImpression ScaleAdolescentsOptimal dose
1983
Differential effects of selective dopamine, norepinephrine or catecholamine depletion on activity and learning in the developing rat
Raskin L, Shaywitz B, Anderson G, Cohen D, Teicher M, Linakis J. Differential effects of selective dopamine, norepinephrine or catecholamine depletion on activity and learning in the developing rat. Pharmacology Biochemistry And Behavior 1983, 19: 743-749. PMID: 6647508, DOI: 10.1016/0091-3057(83)90073-4.Peer-Reviewed Original ResearchConceptsDays of ageT-mazeCentral catecholamine systemsSelective dopamine depletionSelective norepinephrine depletionDopamine depletionNE levelsNorepinephrine depletionCatecholamine depletionSevere learning impairmentIntraperitoneal injectionCatecholamine systemsSelective lesionsDay 28Selective dopamineNeonatal depletionLearning impairmentSelective depletionCatecholaminesClinical researchBehavioral effectsDeficit disorderShuttlebox performanceActivity levelsConstellation of behaviors